Key facts
- This page summarizes Nicholas Mark Johnson's Form 3 filing for MEDIFAST INC (MED).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 27 Mar 2026, 17:55.
Nicholas Mark Johnson - 05 Jan 2026 Form 3 Insider Report for MEDIFAST INC (MED)
- Reporting relationship
- President
- Issuer ticker
- MED
- Reported as of
- 05 Jan 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Jason L. Groves, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Nicholas Mark Johnson filed Form 3 for MEDIFAST INC (MED) on 27 Mar 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002108270
Primary reporting owner
Johnson Nicholas Mark
- Relationship
- President
- Address
- C/O MEDIFAST, INC., 1501 S. CLINTON STREET, SUITE 500, BALTIMORE
- Signature
- /s/ Jason L. Groves, attorney-in-fact
- Signature date
- 27 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MED
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 18,776
- Date
- 05 Jan 2026
- Ownership
- Direct
MED
holding
Common Stock (Restricted Stock Unit)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,428
- Date
- 05 Jan 2026
- Ownership
- Direct
- Footnotes
- F1
MED
holding
Common Stock (Restricted Stock Unit)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 13,457
- Date
- 05 Jan 2026
- Ownership
- Direct
- Footnotes
- F2
MED
holding
Common Stock (Restricted Stock Unit)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 34,906
- Date
- 05 Jan 2026
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MED
holding
Derivative
Stock Options
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 05 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 22,640
- Exercise price
- $66.68
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents a grant of restricted stock units issued to the reporting person under the 2012 Share Incentive Plan that will vest in three equal annual installments beginning on the first anniversary of the grant date, March 13, 2024. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Footnote F2
Represents a grant of restricted stock units issued to the reporting person under the 2012 Share Incentive Plan that will vest in three equal annual installments beginning on the first anniversary of the grant date, March 25, 2025. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Footnote F3
Represents a grant of restricted stock units issued to the reporting person under the 2012 Share Incentive Plan that will vest in three equal annual installments beginning on the first anniversary of the grant date, March 25, 2026. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
SEC remarks
Exhibit List: Exhibit 24 - Limited Power of Attorney.